About HIBio
HIBio is a company based in Foshan (China) founded in 2021 by Travis Murdoch was acquired by Biogen in May 2024. HIBio has raised $215 million across 2 funding rounds from investors including Biogen, Arch Venture Partners and Arkin. HIBio offers products and services including Neurological Therapies. HIBio operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Foshan, China
- Founders Travis Murdoch
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HIBio
HIBio offers a comprehensive portfolio of products and services, including Neurological Therapies.
Treatments for neurological disorders like Alzheimer's
People of HIBio
Unlock access to complete
Leadership Team
2 people
Senior Team
2 people
Chair Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of HIBio
HIBio has successfully raised a total of $215M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $95 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HIBio
HIBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Arch Venture Partners and Arkin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on growth-stage companies
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Jeito Capital is focused on financing medical innovation globally.
|
Locked | Locked | Locked |
Investor details for HIBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HIBio
Investment portfolio details for HIBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HIBio
Detailed financials for HIBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hibio Comparisons
Peer comparison for HIBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HIBio
HIBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of HIBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hibio
Complete news archive for HIBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HIBio
HIBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
HIBio is headquartered in Foshan, China. It is registered at Foshan, Guangdong, China.
Travis Murdoch is the current CEO of HIBio. They have also founded this company.
HIBio is a funded company, having raised a total of $215M across 2 funding rounds to date.
HIBio was founded in 2021 in Foshan, China, by Travis Murdoch, who serves as CEO. Operations focus on the biotechnology sector, where precision medicines targeting autoimmune and inflammatory diseases are developed. Research and development activities are centered in China, with an emphasis on therapeutic innovations for unmet medical needs in immunology. The companys domain, hibio.com, supports its ongoing efforts in this field.
HIBio's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
HIBio offers Neurological Therapies.
HIBio has 7 investors. Key investors include Biogen, Arch Venture Partners, Arkin, Alpha Wave Global, and Viking Global Investors.